Omeros Corporation
Omeros Corporation (OMER) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · OMER · as of Jun 8, 2026
Key Statistics
Explore Omeros Corporation Data
omer stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 19 · Buy rate: 57.9%
The OMER analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $40.00, representing +306.09% upside from the current price of $9.85.
Competitors & Peers
omer competitorsOMER
ADCT
BCYC
FDMT
FULC
GOSSStock Performance
Full HistoryAbout Omeros Corporation
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies,…
what is omeros corporation · omer stock overview · omeros corporation company profile · who is omeros corporation ceo · omer NASDAQ · omeros corporation headquarters · omeros corporation business segments
About Stock Overview & Key Data
Omeros Corporation (OMER) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 8, 2009. As of the latest trading session, OMER stock price is $9.85, with a market capitalization of $712.9M. The stock has returned +160.61% over the past 12 months and -42.81% year-to-date.
According to 19 Wall Street analysts, the consensus rating for Omeros Corporation stock is Buy, with an average 12-month price target of $40.00. In fiscal year 2025, Omeros Corporation reported revenue of — and net income of -$3.4M. For detailed data — including Omeros Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Omeros Corporation (OMER) stock price is $9.85. The stock is traded on NASDAQ under the ticker symbol OMER. The 52-week range is $2.95 – $17.65.